1 Global Sacroiliac Joint Fusion Market Insight Analysis
The global Sacroiliac Joint Fusion market will be valued at USD 461.86 Million in 2025, with a CAGR of 15.39% from 2025 to 2033.
Sacroiliac joint fusion is a surgical procedure which fuses the iliac bone (pelvis) to the spine (sacrum) for stabilization. It is performed for a variety of conditions including trauma, infection, cancer, and spinal instability. There are two sacroiliac joints that connect the sacrum, located at the base of the spine, to the iliac bones, which make up the pelvis. When the ligaments or bony surfaces are damaged, due to trauma, arthritis or other conditions, the sacroiliac joints can be the source of intense pain that may radiate into the leg. Sacroiliac joint fusion is one of the newest and best procedures to provide relief for sacroiliac pain.
Figure Global Sacroiliac Joint Fusion Market Size (M USD) and CAGR (2025-2033)
2 Sacroiliac Joint Fusion Market Growth Drivers and Restraints
Downstream demand growth and rising disease prevalence
As the global population ages, the number of patients with sacroiliac joint dysfunction, degenerative lesions and traumatic injuries has increased significantly. Studies have shown that sacroiliac joint pain may account for 15%-30% of chronic low back pain cases, and with the frequent occurrence of sports injuries and traffic accidents, the demand for surgery continues to rise. In addition, the demand for sacroiliac joint injury repair caused by childbirth in pregnant women has also driven market growth.
The popularity and technical advantages of minimally invasive surgery (MIS)
Minimally invasive surgery has gradually become a mainstream treatment method with its characteristics of less trauma, faster recovery and fewer complications. For example, SI-BONE’s iFuse implant system achieves joint fusion through percutaneous puncture technology, avoiding the risk of large incisions in traditional open surgery. In 2021, minimally invasive surgery accounted for 76.97% of market revenue, and the compound annual growth rate (CAGR) from 2021 to 2026 is expected to be 16.82%, significantly higher than open surgery (9.99%).
Support from medical and reimbursement policies
North America, Europe and other regions have gradually included sacroiliac joint fusion in the scope of medical insurance coverage. For example, Medicare in the United States has expanded reimbursement for minimally invasive surgery, and Humana Inc. also covers SI-BONE’s iFuse system. Policy support has reduced patients’ out-of-pocket costs and increased surgical penetration.
Enterprise strategic expansion and market penetration improvement
Heading companies have accelerated growth through strategic cooperation and international market expansion. For example, Medtronic acquired Intersect ENT to enhance its product line, and Globus Medical entered the field of joint reconstruction through the acquisition of StelKast. In addition, emerging markets (such as China and India) have become the focus of corporate layout due to their large population base and unmet medical needs.
Health awareness and increased medical expenditures
Global per capita medical expenditures have increased, especially in developed countries, where the willingness to pay for high-quality orthopedic surgery has increased. North America accounted for 65.55% of market revenue in 2021, with high purchasing power and a mature medical system as the main supporting factors.
Difficulty in diagnosis and high misdiagnosis rate
The clinical diagnosis of sacroiliac joint dysfunction relies on imaging examinations (such as CT, MRI) and joint injection tests, but it is easy to be confused with lumbar disc herniation, hip joint disease, etc. About 30% of patients miss the best time for surgery due to misdiagnosis, resulting in limited release of market demand.
High surgical costs and reimbursement barriers
Minimally invasive surgical equipment (such as titanium alloy implants) and intraoperative navigation systems are expensive. The cost of a single implant can reach thousands of dollars. Combined with the cost of surgery, the overall treatment cost is high. Developing countries (such as India and Southeast Asia) have low medical insurance coverage and a high proportion of patients paying out of pocket, which limits market growth.
Strict supervision and technical barriers
Europe and the United States have strict approval for medical devices. For example, the FDA requires sacroiliac joint fusion devices to be verified for safety and effectiveness through multi-center clinical trials. The R&D cycle is as long as 5-8 years, and the failure rate is high. It is difficult for emerging companies to enter the market quickly, resulting in a monopoly by leading companies (the top three companies have a market share of 63.36%).
The continued impact of the COVID-19 epidemic
During the epidemic, elective surgeries (such as sacroiliac joint fusion) were postponed, and the global market growth rate dropped to 8.69% in 2020. Supply chain disruptions (such as shortages of titanium raw materials) and hospital resources tilted towards COVID-19 treatment further hindered market recovery.
Although open surgery is gradually replaced by minimally invasive technology, it is still irreplaceable in complex cases (such as tumors and severe infections). In addition, minimally invasive surgery may face risks such as implant loosening and bone fusion failure (the incidence rate is about 5%-8%), which affects patient acceptance.
3 Technological Innovations in the Sacroiliac Joint Fusion Market
Minimally invasive and precision surgical technology
Robotic-assisted navigation: For example, the robotic system developed by Globus Medical controls the implant placement error within 0.1mm through preoperative 3D modeling and real-time guidance during surgery, thereby improving the success rate of fusion.
Biodegradable materials: Some companies are exploring the use of absorbable materials such as polylactic acid (PLA) to replace titanium alloys to avoid the risk of long-term retention of metal implants in the body, which is suitable for young patients.
3D printing and personalized implants
3D printing technology enables precise matching of implants with patient anatomy. For example, Orthofix’s FIREBIRD SI fusion system promotes bone cell growth through 3D printing of porous titanium structures, increasing the fusion rate to more than 90%.
Postoperative monitoring and remote management
Smart implants integrate pressure sensors to monitor joint stability in real time, transmit data to the doctor via Bluetooth, and warn of complications (such as implant displacement) in advance. SI-BONE is developing such Internet of Things (IoT) solutions and plans to commercialize them in 2024.
Technical supplements for non-surgical treatments
Extracorporeal shock wave therapy (ESWT) and platelet-rich plasma (PRP) injections, as conservative treatments before surgery, do not directly replace surgery, but they have promoted the market’s awareness of “step-by-step treatment” and indirectly expanded overall demand.
Horizontal expansion of leading companies
SI-BONE: As a leader in minimally invasive surgery (market share of 36% in 2021), it has expanded its production capacity through debt refinancing (US$40 million) and laid out the Asia-Pacific market.
Medtronic: Acquired Intersect ENT (US$1.1 billion), integrated its minimally invasive otolaryngology technology, and fed back surgical navigation research and development in the orthopedic field.
Vertical integration in sub-sectors
Zimmer Biomet: Acquired A&E Medical (US$250 million), obtained sternal closure devices and surgical tools, and improved its spinal surgery product line, especially in complex fusion cases to form synergies.
Orthofix: Acquired the FITBONE limb lengthening system to expand technology to non-fusion treatments for scoliosis and reduce dependence on traditional fusion surgery.
4 Global Sacroiliac Joint Fusion Market Size by Type
Breaking down the market by type, Minimally Invasive Surgery (MIS) emerges as the dominant segment. In 2025, MIS is expected to generate a revenue of $372.97 million USD. This type of surgery is favored for its less invasive nature, leading to quicker recovery times and fewer complications, thus driving its adoption.
On the other hand, Open Surgery of Sacroiliac Joint Fusion, while less popular due to its more invasive nature, still holds a substantial share of the market. By 2025, this segment is projected to contribute $88.89 million USD to the total revenue. Despite advancements in minimally invasive techniques, open surgery remains crucial in certain complex cases where a more direct approach is necessary.
Table Global Sacroiliac Joint Fusion Market Size by Type in 2025
|
Type |
Market Size (M USD) 2025 |
|---|---|
|
Minimally Invasive Surgery |
372.97 |
|
Open Surgery of Sacroiliac Joint Fusion |
88.89 |
5 Global Sacroiliac Joint Fusion Market Size by Application
In 2025, the market revenue for sacroiliac joint fusion in hospitals is forecasted to reach 340.98 million US dollars. Hospitals have always been the primary setting for sacroiliac joint fusion procedures. This is mainly because they offer a comprehensive range of medical services and resources.
Hospitals are equipped with advanced diagnostic facilities, such as high – resolution CT scanners and MRI machines, which are essential for accurately diagnosing sacroiliac joint disorders. Moreover, they house highly skilled orthopedic surgeons and medical teams who are trained to handle complex surgical cases. The presence of intensive care units and post – operative care facilities in hospitals also ensures the safety and well – being of patients undergoing sacroiliac joint fusion surgery.
In addition, hospitals often serve as centers for medical research and innovation. They are more likely to adopt the latest surgical techniques and technologies, such as minimally invasive procedures and the use of 3D – printed implants. This not only improves patient outcomes but also attracts a large number of patients seeking advanced treatment options, thereby driving the market revenue in this segment.
The market revenue for sacroiliac joint fusion in Ambulatory Surgical Centers (ASCs) is projected to be 120.89 million US dollars in 2025. ASCs have been gaining popularity in recent years as an alternative to traditional hospital – based surgeries.
ASCs offer several advantages. They typically have lower overhead costs compared to hospitals, which can translate into cost savings for patients. This cost – effectiveness, combined with the convenience of same – day surgery, makes ASCs an attractive option for many patients. In the context of sacroiliac joint fusion, ASCs are increasingly being equipped to handle less complex cases, especially those that can be managed using minimally invasive techniques.
Furthermore, the regulatory environment in some regions is becoming more favorable for ASCs, allowing them to perform a wider range of surgical procedures. As the technology for sacroiliac joint fusion continues to advance and become more streamlined, ASCs are expected to play an even more significant role in the market. The growth of this segment is also indicative of the evolving healthcare landscape, where patient – centric, cost – efficient, and convenient healthcare delivery models are in high demand.
Table Global Sacroiliac Joint Fusion Market Size by Application in 2025
|
Application |
Market Size (M USD) 2025 |
|---|---|
|
Hospitals |
340.98 |
|
ASC |
120.89 |
6 Global Sacroiliac Joint Fusion Market Size by Region
North America leads the global sacroiliac joint fusion market in terms of revenue. In 2025, the market size in North America reached 300.52 million US dollars. This region has a well – developed healthcare infrastructure, high levels of healthcare spending, and a large patient pool due to factors like an aging population and a high incidence of sports – related injuries.
The healthcare system in North America is highly advanced, with a wide availability of state – of – the – art medical facilities and skilled medical professionals. This has facilitated the adoption of new and innovative sacroiliac joint fusion techniques. Additionally, the presence of major medical device companies and research institutions in the region has spurred continuous technological advancements in this field. For example, the development of minimally invasive surgical (MIS) techniques has been actively promoted in North America, which has not only improved patient outcomes but also contributed to the growth of the market. The high reimbursement rates for sacroiliac joint fusion procedures in many North American countries also play a crucial role in driving the market growth.
Europe is another significant market for sacroiliac joint fusion. In 2025, the market size in Europe was 85.88 million US dollars. Europe has a long – standing tradition of advanced medical research and healthcare provision. The region has a large number of patients suffering from sacroiliac joint disorders, mainly due to factors such as a high prevalence of osteoporosis in the aging population and an increasing number of trauma – related cases.
European countries have been actively investing in healthcare innovation, with a focus on improving patient care and reducing the burden of chronic diseases. The adoption of new surgical technologies, such as 3D – printed implants and robotic – assisted surgery, is on the rise in Europe. However, there are some challenges in this region as well. The fragmented healthcare systems across different European countries, along with varying reimbursement policies, can sometimes pose barriers to the widespread adoption of new sacroiliac joint fusion technologies. Nevertheless, with continuous efforts in research and development and the increasing awareness about the importance of treating sacroiliac joint disorders, the European market is expected to maintain a steady growth rate.
China’s sacroiliac joint fusion market size reached 29.53 million US dollars in 2025. China has a large population, which inherently means a significant patient base for sacroiliac joint fusion procedures. In recent years, with the continuous improvement of China’s economic level, there has been a substantial increase in healthcare investment.
The Chinese government has been actively promoting the development of the medical device industry, which has led to the emergence of many domestic medical device manufacturers. These local companies are gradually catching up in terms of technology and quality, competing with international brands in the domestic market. Moreover, the increasing awareness of the importance of orthopedic health among the Chinese population, along with the expansion of medical insurance coverage, has contributed to the growth of the sacroiliac joint fusion market.
Although China’s market size is currently smaller compared to North America and Europe, its rapid growth potential cannot be underestimated. With the continuous improvement of medical technology and the expansion of the healthcare market, China is likely to play an increasingly important role in the global sacroiliac joint fusion market in the future.
Figure Global Sacroiliac Joint Fusion Market Size (M USD) by Region in 2025
7 Global Sacroiliac Joint Fusion Market Analysis by Major Players
SI-BONE
Company Profile: SI-BONE, established in 2008 and headquartered in the USA, is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. The company operates worldwide and has a strong focus on minimally invasive surgical solutions.
Business Overview: SI-BONE is renowned for pioneering the iFuse Implant System, a minimally invasive surgical system for fusion of the sacroiliac joint to treat sacroiliac joint dysfunction. The iFuse Implant, commercially available since 2009, is supported by multiple prospective clinical studies showing improved pain, patient function, and quality of life resulting from treatment. SI-BONE continues to monitor and adhere to the latest safety guidelines established by health authorities and offers web-based training on telehealth and other relevant topics for healthcare providers (HCPs).
Product Offered: The flagship product, the iFuse Implant System®, is designed to provide immediate sacroiliac (SI) joint stabilization and allow long-term fusion. It is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction resulting from sacroiliac joint disruption and degenerative sacroiliitis. The system includes triangular titanium implants that are specifically constructed to stabilize and fuse the SI joint, with a porous titanium surface that allows for bony ongrowth/ingrowth.
Medtronic
Company Profile: Medtronic, founded in 1949 and headquartered in the USA, is a global leader in medical technology with a presence in over 150 countries. The company is known for its broad range of medical devices that treat over 70 health conditions.
Business Overview: Medtronic’s commitment to improving lives through medical technology is evident in its diverse product portfolio, which includes cardiac devices, cranial and spine robotics, insulin pumps, surgical tools, patient monitoring systems, and more. The company has been particularly active in developing innovative solutions for spine surgeries, including sacroiliac joint fusion.
Product Offered: Medtronic offers the Rialto SI Fusion System, designed to stabilize the sacroiliac joint and provide an environment for fusion. The system consists of cylindrical threaded devices that enhance sacroiliac joint fusion. These devices are minimally invasive and can be inserted through a small incision with minimal tissue disruption. The system also allows for the delivery of bone graft within the device to promote fusion, offering a comprehensive solution for sacroiliac joint stabilization and fusion.
Globus Medical
Company Profile: Globus Medical, established in 2003 and headquartered in the USA, is a leading medical device manufacturer focused on improving the quality of life for patients with musculoskeletal disorders. The company operates worldwide and is dedicated to providing innovative solutions for spine surgeries.
Business Overview: Globus Medical is inspired by the needs of patients and the surgeons who treat them. The company ensures a continuous supply of medical technology to meet the increased demand for treatments. Globus Medical’s operations, manufacturing, and supply chain are fully functional, yielding a strong supply of inventory to service the market.
Product Offered: The SI-LOK® Sacroiliac Joint Fusion System is one of Globus Medical’s key offerings. This system includes hydroxyapatite (HA) coated screws, cannulated drill bits, and wires designed for a lateral approach to the sacroiliac (SI) joint. The features promote fusion, with fully threaded connections for security, large diameter screws for strength, and optional graft slots to further encourage fusion. This system is designed to provide a strong, stable fusion environment for the sacroiliac joint.